Efficacy of ruxolitinib for HAVCR2 mutation‐associated hemophagocytic lymphohistiocytosis and panniculitis manifestations in children
- 16 April 2023
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 202 (1) , 135-146
Abstract
Summary: Frequent germline mutations of HAVCR2, recently identified in subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL), are associated with an increased risk of hemophagocytic lymphohistiocytosis (HLH). However, SPTCL‐HLH represents a challenge because of the difficulties in treatment with poor survival. Its malignant nature, specifically harbouring HAVCR2 mutations, has also been questioned. To better understand its pathology and treatment, we analysed the clinical data of six patients diagnosed at our centre. The median age at onset was 10.5 years (range, 0.8–12.4). Five patients presented with skin lesions of subcutaneous nodules/plaques and/or ulceration. All patients developed HLH; notably, one infant only had HLH without skin involvement. Histopathologically, only two patients were diagnosed with SPTCL and three were reported as panniculitis with no sufficient evidence of lymphoma. Genetically, germline homozygous mutation of HAVCR2 (p.Y82C) was identified in all patients, with a median diagnosis time of 4.6 months. All patients initially received corticosteroids, immunosuppressants or chemotherapy, achieving unfavourable responses. Strikingly, they responded well to ruxolitinib targeting inflammatory cytokines, allowing rapid disease resolution and/or long‐term maintenance of remission. The excellent efficacy of ruxolitinib highlights this disease as an inflammatory condition instead of neoplastic nature and indicates novel agents targeting key inflammatory pathways as an encouraging approach for this disease entity.Keywords
Funding Information
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park (Z221100007422054)
This publication has 23 references indexed in Scilit:
- Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitis‐like T‐cell lymphomaBritish Journal of Haematology, 2017
- Subcutaneous Panniculitis-like T-cell Lymphoma: Immunosuppressive Drugs Induce Better Response than PolychemotherapyActa Dermato-Venereologica, 2017
- Cutaneous lymphomas with a panniculitic presentationSeminars in Diagnostic Pathology, 2017
- Subcutaneous panniculitis-like T-cell lymphoma in children: a detailed clinicopathological description of 11 multifocal cases with a high frequency of haemophagocytic syndromeBritish Journal of Dermatology, 2015
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia VeraNew England Journal of Medicine, 2015
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for MyelofibrosisNew England Journal of Medicine, 2012
- Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 casesBlood, 2008
- HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2006
- Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis‐like T‐cell lymphomaCancer, 2004
- Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral toleranceNature Immunology, 2003